Published in Lab Invest on October 01, 1980
Carpal tunnel syndrome caused by amyloid containing beta 2 microglobulin: a new amyloid and a complication of long term haemodialysis. Ann Rheum Dis (1986) 0.99
Demonstration of AA-protein in formalin-fixed, paraffin-embedded tissues. Am J Pathol (1982) 0.93
Characterization of amyloid deposits in biopsies of 15 with "sporadic" (non-familial or plasma cell dyscrasia amyloid polyneuropathy. Acta Neuropathol (1986) 0.89
Nature of amyloid deposits in hypernephroma. Immunocytochemical studies in 2 cases associated with amyloid polyneuropathy. Am J Pathol (1984) 0.85
Morphologic demonstration of cytoplasmic ASSAM-related antigenic substance (CASSAM) by an immunoperoxidase technique. Am J Pathol (1985) 0.83
Amyloid Deposits in Pituitaries and Pituitary Adenomas: Immunohistochemistry and In Situ Hybridization. Endocr Pathol (1995) 0.81
Focal intracerebral accumulation of a novel type of amyloid protein. An early stage of cerebral amyloidoma? Acta Neuropathol (1988) 0.75
Cardiac amyloidosis diagnosed by endomyocardial biopsy. Korean J Intern Med (1988) 0.75
Light and electron microscopic studies of localized laryngeal amyloidosis. Arch Otorhinolaryngol (1987) 0.75
Immunohistological characterisation of amyloid deposits in renal biopsy specimens. J Clin Pathol (1991) 0.75
Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun (1984) 20.07
Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts). N Engl J Med (1980) 9.38
Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun (1984) 8.14
Scrapie prions aggregate to form amyloid-like birefringent rods. Cell (1983) 7.92
Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA (2001) 5.54
Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med (1976) 5.16
X-ray diffraction studies on amyloid filaments. J Histochem Cytochem (1968) 4.54
Amyloid fibril proteins: proof of homology with immunoglobulin light chains by sequence analyses. Science (1971) 4.27
Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med (1986) 4.01
Amyloid deposits and amyloidosis: the beta-fibrilloses (second of two parts). N Engl J Med (1980) 3.95
Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related. Proc Natl Acad Sci U S A (1985) 3.54
Creation of "amyloid" fibrils from Bence Jones proteins in vitro. Science (1971) 3.14
Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int (1984) 3.10
Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med (2001) 2.77
Beta-pleated sheet fibrils. A comparison of native amyloid with synthetic protein fibrils. J Histochem Cytochem (1974) 2.69
Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet (1992) 2.38
Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med (1983) 2.38
Nephrotic syndrome: an under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation. Br J Haematol (2005) 2.32
Differences between vascular and plaque core amyloid in Alzheimer's disease. J Neurochem (1988) 2.24
Amyloidosis: its nature and pathogenesis. Semin Hematol (1973) 2.21
Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med (1996) 2.17
The ultrastructure of human amyloid as revealed by the negative staining technique. J Ultrastruct Res (1966) 2.13
Glucocorticoid suppression of macrophage migration inhibitory factor. J Exp Med (1973) 2.10
Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med (1993) 2.05
Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med (1993) 1.99
A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. Histochemie (1966) 1.98
Amyloid, amyloidosis, and amyloidogenesis. Int Rev Exp Pathol (1976) 1.97
Clinical differences between North African and Iraqi Jews with familial Mediterranean fever. Am J Med Genet (1998) 1.95
Amino acid sequence of an amyloid fibril protein of unknown origin. J Biol Chem (1972) 1.90
Mapping of a gene causing familial Mediterranean fever to the short arm of chromosome 16. N Engl J Med (1992) 1.90
Amyloid fibril protein AA: purification and properties of the antigenically related serum component as determined by solid phase radioimmunoassay. J Immunol (1976) 1.89
NF-kappaB activation is a critical regulator of human granulocyte apoptosis in vitro. J Biol Chem (1999) 1.89
Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int (1994) 1.88
Isolation of a low-molecular-weight serum component antigenically related to an amyloid fibril protein of unknown origin. Proc Natl Acad Sci U S A (1975) 1.84
The immunoglobulin origin of amyloid. Am J Med (1972) 1.64
Prognostic factors after hepatectomy for hepatocellular carcinomas. A univariate and multivariate analysis. Cancer (1990) 1.61
NIH conference. Systemic lupus erythematosus: evolving concepts. Ann Intern Med (1979) 1.59
Morphology and distribution of plaque and related deposits in the brains of Alzheimer's disease and control cases. An immunohistochemical study using amyloid beta-protein antibody. Lab Invest (1989) 1.56
Congophilic angiopathy in the pathogenesis of Alzheimer's degeneration. Ann Pathol (1981) 1.51
Structural identity of Bence Jones and amyloid fibril proteins in a patient with plasma cell dyscrasia and amyloidosis. J Clin Invest (1973) 1.51
The amyloid deposits in Alzheimer's disease: their nature and pathogenesis. Appl Pathol (1984) 1.49
Ultrastructure of the human carotid body. A perspective on the mode of chemoreception. Circulation (1968) 1.48
Human amyloid protein: chemical variability and homogeneity. J Histochem Cytochem (1971) 1.45
High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant (1995) 1.43
Re-examination of ex-boxers' brains using immunohistochemistry with antibodies to amyloid beta-protein and tau protein. Acta Neuropathol (1991) 1.43
Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum (2002) 1.42
Treatment and prognosis of lupus nephritis. J Rheumatol (1994) 1.39
Immunochemical cross-reactions of human amyloid proteins with human immunoglobulin light polypeptide chains. J Immunol (1972) 1.39
A hog kidney aminopeptidase liberating N-terminal dipeptides. Partial purification and characteristics. Acta Chem Scand (1968) 1.38
Outpatient monthly oral bolus cyclophosphamide therapy in systemic lupus erythematosus. J Rheumatol (1996) 1.38
Epstein-Barr virus induces normal B cell responses but defective suppressor T cell responses in patients with systemic lupus erythematosus. J Immunol (1983) 1.37
Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma. Am J Med (1980) 1.36
Histology and ultrastructure of carotid body paragangliomas. Comparison with the normal gland. Cancer (1967) 1.36
Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med (1995) 1.35
Primary localized amyloidosis of the genitourinary tract: immunohistochemical study on eleven cases. Lab Invest (1981) 1.34
Acyclovir-induced renal failure. Clinical course and histology. Am J Med (1988) 1.33
Do the tumor cells of hepatocellular carcinomas dislodge into the portal venous stream during hepatic resection? Cancer (1992) 1.32
The relation of the properties of Congo red-stained amyloid fibrils to the -conformation. J Histochem Cytochem (1972) 1.32
Immunoregulatory disorders associated with hereditary angioedema. I. Clinical manifestations of autoimmune disease. J Allergy Clin Immunol (1986) 1.31
Viscoelastic properties of plant cell walls--I. Mathematical formulation for stress relaxation with consideration for pre-extension rate. Biorheology (1978) 1.30
Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med (1986) 1.29
Treatment of type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies. J Clin Endocrinol Metab (2010) 1.29
Model for studying virus attachment: identification and quantitation of Epstein-Barr virus-binding cells by using biotinylated virus in flow cytometry. J Virol (1988) 1.29
Immunosuppressive effects of glucocorticosteroids: differential effects of acute vs chronic administration on cell-mediated immunity. J Immunol (1975) 1.26
Murine amyloidosis: immunologic characterization of amyloid fibril protein. J Immunol (1971) 1.25
Congophilic microangiopathy in the pathogenesis of Alzheimer's syndrome (presenile dementia). Med Hypotheses (1979) 1.24
Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors. Medicine (Baltimore) (1985) 1.24
Local steroid injection into the artificial ulcer created by endoscopic submucosal dissection for gastric cancer: prevention of gastric deformity. Endoscopy (2012) 1.22
Physical and chemical properties of amyloid fibers. II. Isolation of a unique protein constituting the major component from human splenic amyloid fibril concentrates. J Histochem Cytochem (1969) 1.21
An amyloid fibril protein of unknown origin: partial amino-acid sequence analysis. Biochem Biophys Res Commun (1972) 1.21
Primary amyloidosis. Ann Intern Med (1968) 1.20
Systemic lupus erythematosus: emerging concepts. Part 2: Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Ann Intern Med (1995) 1.19
Murine amyloid fibril protein: isolation, purification and characterization. J Histochem Cytochem (1971) 1.17
Glucocorticosteroid action on the immune system: molecular and cellular aspects. Clin Exp Rheumatol (1991) 1.17
Amyloid A: amphipathic helixes and lipid binding. Biochemistry (1976) 1.15
High-affinity antibodies to ssDNA are produced by CD-B cells in systemic lupus erythematosus patients. J Immunol (1989) 1.15
Renal vasculitis. Kidney Int (1985) 1.15
Evidence of amyloid beta-protein immunoreactive early plaque lesions in Down's syndrome brains. Lab Invest (1989) 1.13
Infrared spectroscopy of human amyloid fibrils and immunoglobulin proteins. Biopolymers (1972) 1.13
Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus. Ann Intern Med (1990) 1.12
The purification of amyloid fibril proteins. Prep Biochem (1972) 1.12
Purification of aminopeptidase A in human serum and degradation of angiotensin II by the purified enzyme. Biochim Biophys Acta (1970) 1.12
Immunoglobulin origin of localized nodular pulmonary amyloidosis. Res Exp Med (Berl) (1972) 1.11
Deficient gamma-interferon production in patients with systemic lupus erythematosus. Arthritis Rheum (1986) 1.11
Effect of treatment on the evolution of renal abnormalities in lupus nephritis. N Engl J Med (1984) 1.11
Role of Fc receptors in herpes simplex virus infection. Lancet (1975) 1.11
Parathyroid hyperplasia and parathyromatosis. Lancet (1977) 1.10
Outcome criteria for lupus nephritis trials: a critical overview. Lupus (1998) 1.10
On causative theories in Alzheimer's disease. Hum Pathol (1985) 1.09
Modulation of mouse complement receptors 1 and 2 suppresses antibody responses in vivo. J Immunol (1991) 1.09
Evidence for linkage of the gene causing familial Mediterranean fever to chromosome 17q in non-Ashkenazi Jewish families: second locus or type I error? Hum Genet (1993) 1.09
Cyclophosphamide suppression of established cell-mediated immunity. Quantitative vs. qualitative changes in lymphocyte populations. J Clin Invest (1975) 1.09
Structure of the VH and VL segments of monoreactive and polyreactive IgA autoantibodies to DNA in patients with systemic lupus erythematosus. J Immunol (1994) 1.08
Biomechanical and biochemical characteristics of the mandibular condylar cartilage. Osteoarthritis Cartilage (2009) 1.08
Characterization of aminopeptidase B: substrate specificity and affector studies. Arch Biochem Biophys (1966) 1.08
Amyloid. VI. A comparison of two morphologic components of human amyloid deposits. J Histochem Cytochem (1968) 1.08
An amyloid protein: the amino-terminal variable fragment of an immunoglobulin light chain. Biochem Biophys Res Commun (1970) 1.08
Activated T lymphocytes in the peripheral blood of patients with systemic lupus erythematosus induce B cells to produce immunoglobulin. Clin Exp Rheumatol (1988) 1.08